TPN729MA (TPN729 maleate) is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC50 value of 2.28 nM. TPN729MA affects erectile function and it can be used for the research of erectile dysfunction.
TPN729MA (1.25, 2.5 and 5.0 mg/kg; intraduodenal injection, once) increases intracavernous pressure/blood pressure (ICP/BP) with the dose of 5.0 mg/kg at all time points and with the dose of 2.5 mg/kg at 75, 90, 105, and 120 minutes time points[1].
TPN729MA (5.0 μg/kg, i.v., once) significantly increases ICP and ICP/BP of male Beagle dogs[1].